Short Interest in Sienna Biopharmaceuticals, Inc. (OTCMKTS:SNNAQ) Drops By 28.6%

Sienna Biopharmaceuticals, Inc. (OTCMKTS:SNNAQ) saw a large decrease in short interest during the month of July. As of July 31st, there was short interest totalling 1,000 shares, a decrease of 28.6% from the July 15th total of 1,400 shares. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio is presently ∞ days.

Sienna Biopharmaceuticals Stock Performance

Sienna Biopharmaceuticals has a one year low of $0.00 and a one year high of $0.00.

Sienna Biopharmaceuticals Company Profile

Sienna Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus.